Novo Nordisk Pharmatech A/S

At Novo Nordisk Pharmatech, we are committed to developing life science solutions that enable medicines for our customers sustainably. We are proud that our innovative research and products help millions of people around the world live better lives. We are committed to making a difference with products that benefit people suffering from serious chronic diseases. We provide products to aid pharmaceutical manufacturing in four product areas: Recombinant Insu-lin, Enzymes, Benzalkonium Chloride, and Resins. We will continue strengthening our partnerships with those customers needing animal-free and reliable ingredients supplied securely and consistent-ly. Quality is our top priority, and we always ensure high batch-to-batch consistency across our prod-ucts according to regulations, with cGMP being a key capability. We have attracted an extensive roster of leading pharmaceutical companies through unsurpassed product quality, manufacturing and quality control, regulatory documentation, precision delivery and a comprehensive risk mitigation strategy. TrypsiNNex® TrypsiNNex® is an animal-free, recombinant porcine trypsin that delivers exceptional performance and consistency for highly regulated biopharma manufacturing processes. Launched in 2024. Recombinant Insulin Recombinant Insulin is used to produce monoclonal antibodies, virus vaccines, gene therapy drugs, and other innovative biologic products approved for use by regulatory bodies worldwide, including FDA and EMA. Benzalkonium Chloride (BKC) BKC is produced according to the highest cGMP standards and backed by complete regulatory doc-umentation. Our Benzalkonium Chloride products have proven efficacy against a broad spectrum of microorganisms through a wide pH range and are soluble in both oily and aqueous phases. We were established in 1949, acquired by Novo Nordisk in 1986 and have been part of the pharma-ceutical group since then.